Back to Journals » Neuropsychiatric Disease and Treatment » Call For Papers

Neuropsychiatric Disease and Treatment


The following Article Collection/ Thematic Series is currently open for submissions:

Beneath the surface: genetic factors in schizophrenia

Dove Medical Press is pleased to invite you to submit your research to an upcoming Thematic Series on "Beneath the surface: genetic factors in schizophrenia", edited by Editor-in-Chief Dr Roger Pinder in Neuropsychiatric Disease and Treatment.

Upon submission, please use the promo code GIIGV for 20% off the advertised article processing charge and indicate that your manuscript will be considered for the Thematic Series of " Beneath the surface: genetic factors in schizophrenia”. The deadline for manuscripts is the 1st of September 2022.

For any enquiries, please email Darcy Hodge, Commissioning Editor at [email protected]

About the Thematic Series

There are a multitude of potential reasons behind the onset of schizophrenia. While some may explain the condition through external factors, such as drug use or trauma, this Thematic Series will consider the potential causes lying low beneath our own genetic material. It has been suggested that certain individuals could be predisposed to schizophrenia, potentially through family members or diathesis-stress models.

Alternative explanations include syndromes and patterns previously referenced in the literature, including 22q11.2 deletion syndrome, schizophrenia onset post-infection, variations in single nucleotide polymorphisms and more.

Genetics do not only feed into literature concerning the onset of schizophrenia. Much rather, treatments have the potential to be adapted to an individual based on genetics, as the influence of pharmacogenomics spreads further into neuropsychiatric illnesses. Therefore, genetics may be able to reveal answers about the origins of schizophrenia, but also the best treatment methods for patients.

The journal is seeking original submissions and review articles on the following topics related to genetic factors in schizophrenia:

• Susceptibility genes for schizophrenia
• miRNA precursors and genetic syndromes (e.g., 22q11.2 deletion syndrome)
• Associations between brain regions linked to immunity and onset of schizophrenia after infection
• Variations in single nucleotide polymorphisms
• Genome wide associations between schizophrenia and specific genes
• Placental gene-expression loci

Submit your manuscript
https://www.dovepress.com/submit_step_1.php

View all papers in this thematic series


Call For Papers

Editor-in-Chief: Dr Roger M Pinder

To see where Neuropsychiatric Disease and Treatment is indexed online view the Journal Metrics

What is the advantage to you of publishing in Neuropsychiatric Disease and Treatment?

  • It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
  • Although Neuropsychiatric Disease and Treatment receives a large number of papers, unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
  • The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Neuropsychiatric Disease and Treatment has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
  • Many authors have found that our peer reviewer’s comments substantially add to their final papers.

To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution a publication processing fee.

PubMed Central
Neuropsychiatric Disease and Treatment is indexed on PubMed Central (title abreviation: Neuropsychiatr Dis Treat).  All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page, you'll just need to supply the working title of your next paper and when you intend to submit by.

Yours sincerely
Dr Roger M. Pinder
Editor-in-Chief
Neuropsychiatric Disease and Treatment

Email: Editor-in-Chief